Document:

EX-4.4(a)

 Exhibit 4.4(a) 

THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT AGREEMENT 

To Purchase Shares of Preferred Stock of 

INTUITY MEDICAL, INC. 

Dated as of December 29, 2017 (the “Effective Date”) 

WHEREAS, Intuity Medical, Inc., a Delaware corporation, has entered into a Loan and Security Agreement of even date herewith (the
“Loan Agreement”) with Hercules Capital, Inc., a Maryland corporation, in its capacity as administrative and collateral agent, Hercules Technology II, L.P., a Delaware limited partnership (the “Warrantholder”), and
the other lender parties thereto; and 
 WHEREAS, the Company (as defined below) desires to grant to the Warrantholder, in
consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right to purchase shares of Preferred Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”). 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial
accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and the Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the
conditions hereinafter set forth, to subscribe for and purchase, from the Company, an aggregate number of fully paid and non-assessable shares of the Preferred Stock equal to the quotient derived by dividing
(a) the Warrant Coverage (as defined below) by (b) the Exercise Price (defined below). The Exercise Price and type of such shares are subject to adjustment as provided in Section 8. As used herein, the following
terms shall have the following meanings: 
 “Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Thirteenth Amended and Restated Certificate of Incorporation, as may be amended from time
to time. 

  
 1 

 “Common Stock” means the Company’s Common Stock, $0.001 par value per
share. 
 “Company” means Intuity Medical, Inc., a Delaware corporation, and any successor or surviving entity that assumes
the obligations of the Company under this Agreement pursuant to Section 8(a). 
 “Exercise Price”
means $0.38 per share, subject to adjustment pursuant to Section 8, subject to adjustment pursuant to Section 8. 

“Initial Public Offering” means the initial underwritten public offering of the Company’s Common Stock pursuant to a
registration statement under the Act, which registration statement has been declared effective by the SEC. 
 “Marketable
Securities” in connection with a Merger Event means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities
Exchange Act of 1934 (as amended, the “1934 Act”), and is then current in its filing of all required reports and other information under the Act and the 1934 Act; (ii) the class and series of shares or other security of the
issuer that would be received by the Warrantholder in connection with the Merger Event were the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities exchange or over-the-counter market, and (iii) following the closing of such Merger Event, the Warrantholder would not be restricted from publicly
re-selling all of the issuer’s shares and/or other securities that would be received by the Warrantholder in such Merger Event were the Warrantholder to exercise this Warrant in full on or prior to the
closing of such Merger Event, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Merger
Event. 
 “Merger Event” means any sale, lease, exclusive license or other transfer of all or substantially all assets of
the Company or any merger or consolidation involving the Company in which the Company is not the surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of
preferred stock, other securities or property of another entity. 
 “Preferred Stock” means, the Series 4 Convertible
Participating Preferred Stock, $0.001 par value per share, of the Company, and, to the extent provided in Sections 8(a) and 8(b), any other stock into or for which such Preferred Stock may be converted or exchanged.

 “Purchase Price” means, with respect to any exercise of this Warrant, an amount equal to the Exercise Price as of the
relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Warrant pursuant to such exercise. 

“SEC” means the Securities and Exchange Commission. 

“Warrant Coverage” means $296,250, plus, subject to and contingent on the funding of the Second Term Loan Advance (as
defined in the Loan Agreement) in accordance with the Loan Agreement, $197,500. 

  
 2 

 SECTION 2. TERM OF THE AGREEMENT. 

Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein (the
“Warrant”) shall commence on the Effective Date and shall be exercisable for a period ending 10 years after the Effective Date. 

SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or
from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the
“Notice of Exercise”), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three
(3) business days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as
Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future exercises, if any. 

The Purchase Price may be paid at the Warrantholder’s election either (a) by cash or check, or (b) by surrender of all or a
portion of the Warrant for shares of Preferred Stock to be exercised under this Warrant and, if applicable, an amended Warrant representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”).
If the Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

 
  

					
	Where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Preferred Stock requested to be exercised under this Warrant (inclusive of shares of Preferred Stock surrendered to the Company in payment of the aggregate Exercise Price in connection with a Net
Issuance).
			
		  	A =	  	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
		  	B =	  	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with respect to each share of
Preferred Stock: 

  
 3 

 (i) if the exercise is in connection with the Initial Public Offering, and
if the Company’s registration statement relating to the Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (A) the initial “Price to Public” of the
Common Stock specified in the final prospectus with respect to the Initial Public Offering and (B) the number of shares of Common Stock into which each share of Preferred Stock is then convertible; 

(ii) if the exercise is after, and not in connection with, the Initial Public Offering, then: 

(A) if the Common Stock is traded on a national securities exchange, the fair market value shall be deemed to be the prior day
closing price before the day the current fair market value of the securities is being determined; or 
 (B) if the Common
Stock is traded over-the-counter, the fair market value shall be deemed to be the prior day closing bid and asked price quoted on the NASDAQ system (or similar system)
before the day the current fair market value of the securities is being determined; 
 (iii) if at any time the Common Stock
is not listed on a national securities exchange or quoted in the over-the-counter market, the current fair market value of Preferred Stock shall be the product of
(x) the then-fair market value per share of Common Stock, as determined in good faith by its Board of Directors, and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such
exercise, unless the Company shall become subject to a Merger Event, in which case the fair market value of Preferred Stock shall be deemed to be the per share value received by the holders of the Preferred Stock pursuant to such Merger Event. 

Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended Agreement representing the remaining number of shares and/or
other securities purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof 

(b) Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all shares of Preferred Stock subject
hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section 3(a) (even if not
surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant to Section 3(a). To the
extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the
Warrantholder is to receive by reason of such automatic exercise. 
 SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred
Stock to provide for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the shares of Preferred
Stock issuable hereunder. 

  
 4 

 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional
shares the Company shall make a cash payment therefor upon the basis of the then fair market value of one share of Preferred Stock. 

SECTION 6. NO RIGHTS AS STOCKHOLDER. 

This Agreement does not entitle the Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the exercise of
the Warrant under this Agreement. 
 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. The Warrantholder’s initial
address, for purposes of such registry, is set forth below the Warrantholder’s signature on this Agreement. The Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 
 The
Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger
Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Warrant, the number of shares of
preferred stock or other securities or property (collectively, “Reference Property”) that the Warrantholder would have received in connection with such Merger Event if Warrantholder had exercised this Warrant immediately prior to
the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors and reasonably acceptable to the Warrantholder) shall be made in the application of the provisions of this Agreement
with respect to the rights and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price, the ability of the Warrantholder to elect the class and series of
Preferred Stock as set forth in the definition thereof, and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly as possible, to the purchase rights under this Agreement in
relation to any Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any Merger
Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement; provided that the foregoing assumption requirement shall not apply if the consideration to be paid for or in respect of the
outstanding shares of Preferred Stock in such Merger Event consists solely of cash and/or Marketable Securities (a “Liquid Sale”), in which case this Warrant shall, upon the closing of such Liquid Sale, automatically and without
further action on the part of any party or other person, represent the right to receive, in lieu of the shares 

  
 5 

 
of Preferred Stock, or other capital stock of the Company for which this Warrant is then exercisable, that are issuable hereunder as of immediately prior to the closing of such Liquid Sale, the
consideration payable on or in respect of such shares of Preferred Stock, or other capital stock of the Company for which this Warrant is then exercisable, in such Liquid Sale less the Purchase Price for all such shares of Preferred Stock (or other
capital stock of the Company for which this Warrant is then exercisable), such consideration to include both the consideration payable at the closing of such Liquid Sale and any deferred consideration payable on or in respect of such shares of
Preferred Stock, or other capital stock of the Company for which this Warrant is then exercisable, thereafter, if any, including, but not limited to, payments of amounts deposited at such closing into escrow and payments in the nature of earn-outs,
milestone payments or other performance-based payments, and such consideration shall become payable to the Warrantholder as and when it is paid to the holders of the outstanding shares of Preferred Stock, or other capital stock of the Company for
which this Warrant is then exercisable (such aggregate consideration, the “Aggregate Liquid Sale Consideration”); provided, further, that in connection with a Liquid Sale where the Aggregate Liquid Sale Consideration
would be less than the aggregate Exercise Price in effect immediately prior to the consummation of such Liquid Sale, then this Agreement will automatically expire effective as of immediately prior to the consummation of such Liquid Sale. In
connection with a Merger Event and upon the Warrantholder’s written election to the Company, the Company shall cause this Agreement to be exchanged for the consideration that the Warrantholder would have received if the Warrantholder had chosen
to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this
Section 8(a) shall similarly apply to successive Merger Events. 
 (b) Reclassification of Shares. Except
for Merger Events subject to Sections 8(a) and 8(e), if the Company at any time shall, by combination, reclassification, exchange, conversion or subdivision of securities or otherwise, change any of the securities as
to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been
issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination, reclassification, exchange, conversion, subdivision or other change. The
provisions of this Section 8(b) shall similarly apply to any successive combination, reclassification, exchange, conversion, subdivision or other change. 

(c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Preferred Stock, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares of Preferred Stock issuable hereunder shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be
proportionately increased and the number of shares of Preferred Stock issuable hereunder shall be proportionately decreased. 
 (d)
Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 

  
 6 

 (i) pay a dividend with respect to the Preferred Stock payable in Preferred
Stock, then the Exercise Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to
such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total
number of shares of Preferred Stock outstanding immediately after such dividend or distribution; or 
 (ii) make any other
dividend or distribution with respect to Preferred Stock (or stock into which the Preferred Stock is convertible), except any dividend or distribution specifically provided for in any other clause of this Section 8, then,
in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the Preferred
Stock (or other stock for which the Preferred Stock is convertible) as of the record date fixed for the determination of the stockholders of the Company entitled to receive such dividend or distribution. 

(e) Antidilution Rights. Additional antidilution rights applicable to the Preferred Stock purchasable hereunder are as set forth in the
Charter and shall be applicable with respect to the Preferred Stock issuable hereunder (for the avoidance of doubt, any waivers of antidilution adjustments with respect to the Preferred Stock effected from time to time in accordance with the terms
of the Charter shall be applicable with respect to the Preferred Stock issuable hereunder). The Company shall promptly provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter applicable to the Preferred Stock
or any other securities for which this Warrant shall then be exercisable; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock as of the Effective Date
unless such amendment, modification or waiver applies to all then outstanding shares of Preferred Stock in the same manner. In the event of any issuance by the Company of any of its stock or other equity security after the Effective Date of this
Agreement that results in the application of antidilution rights for the Preferred Stock purchasable hereunder, the Company shall provide the Warrantholder with notice of such issuance within ten (10) days following the closing of such
issuance, and the Company shall provide the Warrantholder with such information as the Warrantholder reasonably requests in connection with Warrantholder’s determination of the effect of such issuance on this Warrant. The Company shall provide
the Warrantholder with such information as is reasonably necessary for the Warrantholder to determine the effect of such issuances on this Warrant. For the avoidance of doubt, there shall be no duplicate antidilution adjustment pursuant to this
subsection (e), the foregoing subsection (d) and the Charter. 
 (f) Notice of Adjustments. If: (i) the Company shall
declare any dividend or distribution upon its stock, whether in stock, cash, property or other securities; (ii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (iii) the Company shall sell, lease,
exclusively license or otherwise transfer all or substantially all of its assets; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall send to
the Warrantholder: (A) at least fifteen (15) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken 

  
 7 

 
for such dividend or distribution (specifying the date on which the holders of Preferred Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event,
dissolution, liquidation or winding up; (B) in the case of any such Merger Event, sale, lease, exclusive license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least fifteen (15) days’
prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be entitled to exchange their Preferred Stock for securities or other property deliverable upon such Merger Event,
dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, the Company shall give the Warrantholder at least fifteen (15) days’ written notice prior to the effective date of the registration statement
therefor. 
 Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is
required to be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to
purchase hereunder after giving effect to such adjustment, and shall be given in accordance with Section 12(g). 

(g) Timely Notice. Failure to timely provide such notice required by Section 8(f) shall entitle the
Warrantholder to retain the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by the Warrantholder. For purposes of this Section 8(g), and
notwithstanding anything to the contrary in Section 12(g), the notice period shall begin on the date the Warrantholder actually receives a written notice containing all the information required to be provided in such
Section 12(g). 
 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY. 

(a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly and
validly reserved and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of
any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws and pursuant to any agreements, including the Stockholder
Agreements (as defined below), that the Warrantholder may become a party to in connection with such exercise. The Company has made available to the Warrantholder true, correct and complete copies of that certain Eighth Amended and Restated
Investors’ Rights Agreement, dated on or about the Effective Date, by and among the Company and the other parties thereto (the “Rights Agreement”), that certain Seventh Amended and Restated Voting, Right of First Refusal and Co-Sale Agreement, dated on or about the Effective Date, by and among the Company and the other parties thereto (the “ROFR Agreement” and together with the Rights Agreement, the “Stockholder
Agreements”), its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock upon exercise of this Warrant shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost
incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance
and delivery of any certificate in a name other than that of the Warrantholder. 

  
 8 

 (b) Due Authority. The execution and delivery by the Company of this Agreement and
the performance of all obligations of the Company hereunder, including the issuance to the Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all
necessary corporate action on the part of the Company. This Agreement: (i) does not violate the Charter or the Company’s current bylaws; (ii) does not contravene any law or governmental rule, regulation or order applicable to the
Company; and (iii) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which the Company is a party or by which it is bound. This Agreement constitutes a
legal, valid and binding agreement of the Company, enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application affecting
enforcement of creditors’ rights generally. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to,
registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement,
except for any filing required by applicable state securities law, which filings will be effective by the time required thereby. 
 (d)
Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common
Stock, Preferred Stock and any other securities were issued in full compliance with all federal and state securities laws. In addition, as of the date immediately preceding the date of this Agreement: 

(i) The authorized capital of the Company consists of (A) 353,272,950 shares of Common Stock, of which 222,394 shares are
issued and outstanding, (B) 4,856,947 shares of Series 1 Convertible Participating Preferred Stock, of which 4,856,947 shares are issued and outstanding and are convertible into an aggregate of 4,856,947 shares of Common Stock at $1.15 per
share, (C) 32,172,860 shares of Series 2 Convertible Participating Preferred Stock, of which 29,272,426 shares are issued and outstanding and are convertible into an aggregate of 29,272,426 shares of Common Stock at $1.15 per share, (D) 63,500,000
shares of Series 3 Convertible Participating Preferred Stock, of which 60,996,836 shares are issued and outstanding and are convertible into an aggregate of 60,996,836 shares of Common Stock at $1.15 per share and (E) 197,175,000 shares of Series 4
Convertible Participating Preferred Stock, of which no shares are issued and outstanding and are convertible into an aggregate of no shares of Common Stock at $0.38 per share. 

(ii) The Company has reserved 46,079,080 shares of Common Stock for issuance under its Stock Option Plan(s), under which
options to purchase 3,317,422 shares of Common Stock are outstanding. There are warrants outstanding to purchase an aggregate of 2,900,434 shares of Series 2 Convertible Participating Preferred Stock. There are no other options, warrants, conversion
privileges or, except as set forth in the ROFR Agreement, other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other securities of the Company. 

  
 9 

 (iii) No stockholder of the Company has preemptive rights to purchase new
issuances of the Company’s capital stock under the Charter. Certain stockholders of the Company have preemptive rights to purchase new issuances of the Company’s capital stock or other securities under the ROFR Agreement. 

(iv) The lowest issue price per share of Series 4 Convertible Preferred Stock purchased for new money investments in the
initial closing of the transactions under the Series 4 Preferred Stock Purchase Agreement dated December 29, 2017 was $0.38 per share, and the Company has no side letters or other arrangements with any investor providing for any discounts or
reductions to such per share price. 
 (e) Registration Rights. The Company agrees that the shares of Common Stock issued and issuable
upon conversion of the shares of Preferred Stock issued and issuable upon exercise of this Warrant, and, at all times (if any) when the Preferred Stock shall be Common Stock, the shares of Preferred Stock issued and issuable upon exercise of this
Warrant, shall have the “Piggyback” and S-3 registration rights pursuant to and as set forth in the Rights Agreement, as the same may be amended and/or restated from time to time, on a pari passu
basis with the holders of outstanding shares of Preferred Stock who are parties thereto. The provisions set forth in the Rights Agreement relating to such registration rights in effect as of the Effective Date may not be amended, modified or waived
without the prior written consent of the Warrantholder unless such amendment, modification or waiver affects the rights associated with the shares of Preferred Stock issued and issuable upon exercise hereof in the same manner as such amendment,
modification or waiver affects the rights associated with all outstanding shares of Preferred Stock whose holders are parties thereto. 
 (f)
Other Commitments to Register Securities. Except as set forth in this Agreement and the Rights Agreement, the Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act
any of its presently outstanding securities or any of its securities which may hereafter be issued. 
 (g) Exempt Transaction. Subject
to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the Preferred Stock upon exercise of this Warrant, and the issuance of the Common Stock upon conversion of the Preferred Stock, will
each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 

(h) Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock issuable upon the exercise of this Agreement, or the
Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon the Warrantholder’s written request to the Company, the Company shall furnish to the Warrantholder, within ten days after receipt of such
request, a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 

  
 10 

 (i) Information Rights. During the term of this Warrant, the Warrantholder shall be
entitled to the information rights contained in Sections 7.1(a) and (c) of the Loan Agreement, and Sections 7.1(a) and (c) of the Loan Agreement are hereby incorporated into
this Agreement by this reference as though fully set forth herein. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE
WARRANTHOLDER. 
 This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the
Warrantholder: 
 (a) Investment Purpose. The right to acquire Preferred Stock is being acquired for investment and not with a view to
the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of such rights or the Preferred Stock except pursuant to an effective registration statement or an
exemption from the registration requirements of the Act. 
 (b) Private Issue. The Warrantholder understands (i) that the
Preferred Stock issuable upon exercise of this Warrant is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and
qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 

(c) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 
 (d) Risk of No
Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12 of the 1934 Act, or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering
the securities under the Act is not in effect when it desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to
hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in
reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule. 
 (e) Accredited
Investor. The Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 

SECTION 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or
in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when
endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by 

  
 11 

 
the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The
transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its
principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all
purposes. 
 SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to
protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where the Warrantholder
will not have an adequate remedy at law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other person entitled to the benefit of this Agreement
requiring specific performance of any or all provisions hereof or enjoining the Company from continuing to commit any such breach of this Agreement. 

(c) No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the
observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary in order to protect the rights of the
Warrantholder against impairment. 
 (d) Additional Documents. The Company, upon execution of this Agreement, shall provide the
Warrantholder with certified resolutions of the Company’s Board of Directors (i) authorizing the issuance of the Warrant and (ii) reserving for issuance, upon exercise of the Warrant, such number of shares of Preferred Stock as may
from time to time be issuable with respect to the Warrant hereunder and such number of shares of Common Stock as may from time to time be issuable upon conversion of such shares of Preferred Stock. The Company shall also supply documentation
reasonably necessary to evaluate whether to exercise this Warrant, including without limitation, (A) any merger/purchase/asset sale agreement and related documents and estimated payout allocations to each of the respective shareholders, warrant
and option holders in connection with a Merger Event, (B) the most recent capitalization tables, 409A valuations (if any), and board determination of share value (including any waterfall or per share allocations provided to the
share/unitholders), and (C) most recent Charter. 
 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding
between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this
Section 12(e), attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any
kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or
enforce any judgment. 

  
 12 

 (f) Severability. In the event any one or more of the provisions of this Agreement
shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and
enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (g)
Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the
subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a
business day at or before 5:00 pm in the time zone of the recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business
day after deposit with an overnight express service or overnight mail delivery service; or (ii) the third (3rd) calendar day after deposit in the United States mails, with proper first class
postage prepaid, and shall be addressed to the party to be notified as follows: 
 If to the Warrantholder: 

HERCULES TECHNOLOGY II, L.P. 

Legal Department 

Attention: Chief Legal Officer and Anup Arora 

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 

Facsimile: [***] 

Telephone: [***] 
 With a copy to
(which shall not constitute notice): 
 Arnold & Porter Kaye Scholer LLP 

250 W. 55th Street, New York, NY 10019 

Attention: Michael Penney 

Facsimile: [***] 

Telephone: [***] 
  

	(i)	 If to the Company: 

Intuity Medical, Inc. 

3500 W. Warren Ave. 

Fremont, CA 94538 

Attention: Chief Executive Officer, Chief Financial Officer 

Telephone: [***] 

  
 13 

 With a copy to (which shall not constitute notice): 

Latham & Watkins LLP 

140 Scott Drive 

Menlo Park, CA 94025 

Attention: Kathleen Wells 

Facsimile: [***] 

Telephone: [***] 

Email: [***] 
 or to such other
address as each party may designate for itself by like notice. 
 (h) Entire Agreement; Amendments. This Agreement constitutes the
entire agreement and understanding of the parties hereto in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written
or oral, with respect to the subject matter hereof (including the Warrantholder’s proposal letter dated December 6, 2017). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto.

 (i) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof. 
 (j) No Strict Construction. The parties hereto have participated jointly
in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall
arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 (k) No Waiver. No omission
or delay by the Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or
remedy to which the Warrantholder is entitled, nor shall it in any way affect the right of the Warrantholder to enforce such provisions thereafter. 

(l) Survival. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto
shall be for the benefit of the Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

(m) Governing Law. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall have been
accepted by the Warrantholder in the State of California. Delivery of the Preferred Stock to the Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

  
 14 

 (n) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under
or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (i) consents
to personal jurisdiction in Santa Clara County, State of California; (ii) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (iii) agrees not to assert any defense based on lack of jurisdiction or
venue in the aforesaid courts; and (iv) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall
be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall
affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 

(o) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and
economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.
EACH OF THE COMPANY AND THE WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY
THE COMPANY AGAINST THE WARRANTHOLDER OR ITS ASSIGNEE OR BY THE WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve persons other than Company and the Warrantholder; Claims that
arise out of or are in any way connected to the relationship between the Company and the Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this
Agreement. 
 (p) Judicial Reference. If the waiver of jury trial set forth above is ineffective or unenforceable, the parties agree
that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding
Judge of Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(q) Prejudgment Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent
jurisdiction identified in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are
otherwise subject to resolution by judicial reference. 
 (r) Counterparts. This Agreement and any amendments, waivers, consents or
supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the
same instrument. 

  
 15 

 [Remainder of Page Intentionally Left Blank] 

  
 16 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date. 
  

							
	COMPANY:	 		 	INTUITY MEDICAL, INC.
				
		 		 	By:	 	 /s/ Emory V. Anderson

		 		 	Name:	 	Emory V. Anderson
		 		 	Title:	 	President and Chief Executive Officer
			
	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY II, L.P.,
		 		 	a Delaware limited partnership
				
		 		 	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
				
		 		 	By:	 	Hercules Capital, Inc., its Manager
				
		 		 	By:	 	 /s/ Jennifer Choe

		 		 	Name:	 	Jennifer Choe
		 		 	Its:	 	Assistant General Counsel

  
 17 

 EXHIBIT I 

NOTICE OF EXERCISE 
 To: Intuity Medical,
Inc. 
  

	(1)	 The undersigned Warrantholder hereby elects to purchase [ ] shares of the Series
[ ] Preferred Stock of Intuity Medical, Inc., pursuant to the terms of the Warrant Agreement dated December 29, 2017 (the “Agreement”) between Intuity Medical, Inc. and the Warrantholder, and [CASH
PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

 

	(2)	 Please issue a certificate or certificates representing said shares of Series [ ]
Preferred Stock in the name of the undersigned or in such other name as is specified below. 

  

	
	  

	(Name)
	
	  

	(Address)

  

	(3)	 By its execution below and for the benefit of the Company, Warrantholder hereby restates each of the
representations and warranties in Section 10 of the Warrant Agreement as of the date hereof. 

  

							
	WARRANTHOLDER:	 		 	HERCULES TECHNOLOGY II, L.P.,
		 		 	a Delaware limited partnership
				
		 		 	By:	 	Hercules Technology SBIC Management, LLC, its General Partner
				
		 		 	By:	 	Hercules Capital, Inc., its Manager
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Its:	 	  

  
 18 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The
undersigned Intuity Medical, Inc., a Delaware corporation, hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology II, L.P., to purchase [____] shares of the Series [____] Preferred Stock of Intuity Medical,
Inc., pursuant to the terms of the Warrant Agreement by and between Hercules Technology II, L.P. and Intuity Medical, Inc., dated December 29, 2017 (the “Agreement”), and further acknowledges that [__] shares remain subject to
purchase under the terms of the Agreement. 
  

							
	COMPANY:	 		 	INTUITY MEDICAL, INC.
				
		 		 	By:	 	  

		 		 	Name:	 	  

		 		 	Its:	 	  

  
 19 

 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign
the foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

	
	  

	(Please Print)

 whose address is
                                         
                                         
                                         
                                         
                                         
            
  
  

 
  

	
	Dated:
                                         
                                         
                              
	Holder’s Signature:
                                         
                                         
            
	Holder’s Address:
                                         
                                         
              
	                                      
                                         
                                         
        

  

	
	Signature Guaranteed:
                                         
                                         
                                         
                                         
                                         
 

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without
alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 20EX-4.4(b)

 Exhibit 4.4(b) 

Execution Version 
 FIRST
AMENDMENT TO WARRANT AGREEMENT 
 THIS FIRST AMENDMENT (this “Amendment”), dated as of December 27, 2018, to the
Warrant Agreement to Purchase Shares of Preferred Stock of Intuity Medical, Inc., originally dated as of December 29, 2017 (the “Warrant Agreement”), is made by and between INTUITY MEDICAL, INC., a Delaware corporation (the
“Company”), and HERCULES CAPITAL, INC., a Delaware corporation (the “Warrantholder”). 
 A. The Company and
the Warrantholder desire to amend the Warrant Agreement as set forth herein, such modifications to be effective as of the date hereof. 
 B.
The Warrant may be amended pursuant to Section 12(h) thereof by the written agreement of the Company and the Warrantholder, each of which is a party to this Amendment. 

AGREEMENT 
 NOW,
THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Amendments to the Warrant Agreement. The Company and Warrantholder hereby agree to the following amendments to the Warrant Agreement.

 (A) The following definition of “Equity Round” is hereby added to Section 1 of the Warrant Agreement in its proper
alphabetical order: 
 ““Equity Round” means any non-public offering of equity
securities by the Company, completed after the Effective Date but prior to the consummation of an Initial Public Offering, in a transaction or series of related transactions principally for equity raising purposes in which the cash proceeds are
received by the Company and/or debt of the Company is cancelled or converted in exchange for equity securities of the Company. “Equity Round” shall include additional closings of the sale and issuance of any Series 4 Preferred Stock so
long as the gross proceeds to the Company from such additional closings are at least $15 million in the aggregate.” 
 (B) The
following definition of “Next Round” is hereby added to Section 1 of the Warrant Agreement in its proper alphabetical order: 

““Next Round” means the next Equity Round after December 27, 2018 in which the Company issues and sells shares of
its preferred stock and any options, warrants, rights or other securities that are exercisable, convertible or exchangeable into, or otherwise provide the right to purchase or acquire shares of preferred stock of the Company.” 

(C) The following definition of “Series 4 Preferred Stock” is hereby added to Section 1 of the Warrant Agreement in its
proper alphabetical order: 
 ““Series 4 Preferred Stock” means the Series 4 Convertible Participating Preferred
Stock, $0.001 par value per share, of the Company.” 
  

 (D) The definition of “Exercise Price” is hereby amended and restated in
its entirety to read as follows: 
 ““Exercise Price” means (a) if Preferred Stock means the Series 4 Preferred
Stock, $0.38 per share, or (b) if Preferred Stock means Next Round Stock, the lowest cash price per share of Next Round Stock paid by investors in the Next Round, in each case subject to adjustment pursuant to the applicable provisions of this
Warrant Agreement.” 
 (E) The definition of “Preferred Stock” is hereby amended and restated in its entirety to read
as follows: 
 ““Preferred Stock” means, at the election of the Warrantholder, (a) the Series 4 Preferred Stock
or (b) following the closing of the Next Round, the class and series of the preferred stock of the Company and any options, warrants, rights or other securities that are exercisable, convertible or exchangeable into, or otherwise provide the
right to purchase or acquire shares of preferred stock issued in the Next Round (such equity securities, the “Next Round Stock”), and (c) any other stock into or for which the Preferred Stock may be converted or
exchanged.” 
 (F) Section 9(a) of the Warrant Agreement is hereby amended and restated in its entirety to read as follows: 

“(a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has been duly
and validly reserved (or, in the case of the Preferred Stock issued in the Next Round, will be duly and validly reserved) and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on
transfer under state and/or federal securities laws and pursuant to any agreements, including the Stockholder Agreements (as defined below), that the Warrantholder may become a party to in connection with such exercise. The Company has made
available to the Warrantholder true, correct and complete copies of that certain Eighth Amended and Restated Investors’ Rights Agreement, dated on or about the Effective Date, by and among the Company and the other parties thereto (the
“Rights Agreement”), that certain Seventh Amended and Restated Voting, Right of First Refusal and Co-Sale Agreement, dated on or about the Effective Date, by and among the Company and the
other parties thereto (the “ROFR Agreement” and together with the Rights Agreement, the “Stockholder Agreements”), its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock upon
exercise of this Warrant shall be made without charge to the Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock;
provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder.” 

  
 2 

 (G) Section 9 of the Warrant Agreement is hereby amended by adding a new clause (j) to
such section to read in its entirety as follows: 
 “(j) Market Standoff. The Warrantholder agrees to be subject to
Section 1.14 of the Rights Agreement to the same extent as the “Holders” party to the Rights Agreement are subject to such Section 1.14.” 

(H) Exhibit II to the Warrant Agreement is hereby amended and restated in its entirety with the version of Exhibit II attached as Exhibit
A hereto. 
 2. Effect on Warrant Agreement. Except as specifically amended hereby, the Warrant Agreement shall continue to be in
full force and effect and is hereby in all respects ratified and confirmed. The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the Warrantholder under the Warrant Agreement, and
it does not constitute a waiver of any provision of the Warrant Agreement. 
 3. Capitalized Terms. Capitalized terms that are not
otherwise defined in this Amendment, but that are used herein (including as may be used in the Recitals), shall have the respective meanings given to them in the Warrant Agreement. 

4. Governing Law. This Amendment shall be governed by, and construed in accordance with, the law of the State of California. 

5. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Delivery by facsimile, .pdf or other electronic imaging means of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart
of this Amendment. The Warrantholder may also require that any such documents and signatures delivered by facsimile, .pdf or other electronic imaging means be confirmed by a manually signed original thereof; provided that the failure to
request or deliver the same shall not limit the effectiveness of any document or signature delivered by facsimile, .pdf or other electronic imaging means. 

[Remainder of page intentionally blank] 

  
 3 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Warrant
Agreement as of the date first set forth above. 
  

			
	Company:
	
	INTUITY MEDICAL, INC.
		
	By:	 	 /s/ Emory V. Anderson

		 	Name: Emory V. Anderson
		 	Title: President and Chief Executive Officer
	
	Warrantholder:
	
	HERCULES CAPITAL, INC.
		
	By:	 	 /s/ Jennifer Choe

		 	Name: Jennifer Choe
		 	Title: Assistant General Counsel

 EXHIBIT A 

Exhibit II 
 Acknowledgement of
Exercise 
 The undersigned Intuity Medical, Inc., a Delaware corporation, hereby acknowledge receipt of the “Notice of Exercise” from Hercules
Capital, Inc., to purchase [__] shares of the Series [__] Preferred Stock of Intuity Medical, Inc., pursuant to the terms of the Warrant Agreement by and between Hercules Capital, Inc. and Intuity Medical, Inc., dated December 29, 2017 (as
amended, the “Agreement”), and further acknowledges that [__] shares remain subject to purchase under the terms of the Agreement. 
  

							
	COMPANY:	 		 	INTUITY MEDICAL, INC.
				
		 		 	By:	 	  

		 		 	Title:	 	  

		 		 	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]